[Skip to Navigation]
Views 465
Citations 0
Comment & Response
May 28, 2020

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Author Affiliations
  • 1Pharmacology Department, University of Sevilla, Sevilla, Spain
  • 2Pharmacy Department, Hospital Universitario de Puerto Real, Puerto Real, Spain
JAMA Oncol. 2020;6(7):1122. doi:10.1001/jamaoncol.2020.1516

To the Editor The MONARCH 2 trial1 compared fulvestrant in combination with abemaciclib or placebo in patients with hormone receptor–positive, ERBB2-negative advanced breast cancer after progression to a prior endocrine therapy. Sledge and colleagues concluded that greater benefits were found in subgroups of patients with visceral metastasis and primary endocrine therapy resistance. This statement is based on earlier separation of the graphical curves and a numerically larger effect observed in overall survival (OS). However, no statistical interaction was presented in these subsets.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words